SCHEMBL31292345

SCHEMBL31292345

COC(=O)C(C)(C)c1nccc(CO)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLCG1 P19174 1/20 0.40
BRS3 P32247 1/20 0.34
RXRA P19793 3/20 0.33
GRIN1 Q05586 3/20 0.33
GRIN2B Q13224 3/20 0.33
MEN1 O00255 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP2C19 P33261 1/20 0.33
CNR2 P34972 4/20 0.32
CNR1 P21554 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
KCNN4 O15554 1/20 0.31
CCR1 P32246 1/20 0.31
AAK1 Q2M2I8 1/20 0.31
DYRK1A Q13627 1/20 0.31
AR P10275 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31292354 0.87 PLCG1 (0.39) PLCG1BRS3RXRAGRIN1GRIN2B
SCHEMBL31292402 0.83 SHMT1 (0.33) RXRAGRIN1GRIN2BHCRTR1HCRTR2
SCHEMBL24759679 0.80 PLCG1 (0.42) PLCG1BRS3MEN1KMT2ACYP2C19
SCHEMBL31292610 0.80 PLCG1 (0.42) PLCG1MEN1OPRM1OPRD1KMT2A
SCHEMBL24759676 0.78 PLCG1 (0.41) PLCG1BRS3MEN1KMT2ACYP2C19
SCHEMBL24759681 0.78 MTNR1A (0.42) PLCG1BRS3CYP2C19HCRTR1HCRTR2
SCHEMBL12341062 0.77 CCR1 (0.39) RXRAGRIN1GRIN2BHCRTR1HCRTR2
SCHEMBL31292498 0.76 PLCG1 (0.40) PLCG1BRS3KMT2ACYP2C19CNR2
SCHEMBL23355549 0.75 HCRTR1 (0.40) RXRAGRIN1GRIN2BCYP2C19HCRTR1
SCHEMBL31292380 0.73 KDM5A (0.35) RXRAGRIN1GRIN2BHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340528-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-11-06 US disclosed
US-12459920-B2 Targeted protein degradation MONTE ROSA THERAPEUTICS AG (CH) 2025-11-04 US disclosed
US-20250243180-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-07-31 US disclosed
WO-2025024521-A1 SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS, INC. (US) 2025-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243180-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 PLCG1 4629/4885BRS3 4802/4885RXRA 3387/4885
US-12459920-B2 Targeted protein degradation NEK7, NEK1, RIPK1 PLCG1 4630/4885BRS3 4803/4885RXRA 3396/4885
US-20250340528-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 PLCG1 4629/4885BRS3 4802/4885RXRA 3387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.